Concepedia

Author

Roeland Lameris

Amsterdam University Medical CentersORCID

Also Known As

R Lameris, Roeland Lameris

28

Publications

524

Citations

11

H-Index

18

Concepts

All Affiliations

Amsterdam University Medical CentersVrije Universiteit AmsterdamUniversity of AmsterdamLava Therapeutics (Netherlands)Albert Schweitzer Ziekenhuis
RL

About

Roeland Lameris is an author at Amsterdam University Medical Centers specializing in immunology, medicine, and immunotherapy.

Top Concepts

#ConceptH-IndexPublicationsCitations

1

Medicine

3

3

80

2

Cell Biology

3

3

80

3

Immunology

3

3

80

4

Pathology

1

1

21

5

Autoimmunity

1

1

21

Roeland Lameris

×

9

Publications

393

Citations

9

H-Index

YearCitations

A bispecific nanobody approach to leverage the potent and widely applicable tumor cytolytic capacity of Vγ9Vδ2-T cells

Renée C.G. de Bruin, John P. Veluchamy, Sinéad M. Lougheed,

OncoImmunology

2017

82

Preclinical Evaluation of Invariant Natural Killer T Cells Modified with CD38 or BCMA Chimeric Antigen Receptors for Multiple Myeloma

Renée Poels, Esther Drent, Roeland Lameris,

International Journal of Molecular Sciences

2021

65

A Bispecific Single-Domain Antibody Boosts Autologous Vγ9Vδ2-T Cell Responses Toward CD1d in Chronic Lymphocytic Leukemia

Iris de Weerdt, Roeland Lameris, Jurjen M. Ruben,

Clinical Cancer Research

2021

52

Improving CLL Vγ9Vδ2-T–cell fitness for cellular therapy by ex vivo activation and ibrutinib

Iris de Weerdt, Tom Hofland, Roeland Lameris,

Blood

2018

48

A single-domain bispecific antibody targeting CD1d and the NKT T-cell receptor induces a potent antitumor response

Roeland Lameris, Adam Shahine, Daniel G. Pellicci,

Nature Cancer

2020

38

A Bispecific Antibody Antagonizes Prosurvival CD40 Signaling and Promotes Vγ9Vδ2 T cell–Mediated Antitumor Responses in Human B-cell Malignancies

Iris de Weerdt, Roeland Lameris, George L. Scheffer,

Cancer Immunology Research

2020

38

A bispecific T cell engager recruits both type 1 NKT and Vγ9Vδ2-T cells for the treatment of CD1d-expressing hematological malignancies

Roeland Lameris, Jurjen M. Ruben, Victoria Iglesias‐Guimarais,

Cell Reports Medicine

2023

28

Generation and characterization of CD1d‐specific single‐domain antibodies with distinct functional features

Roeland Lameris, Renée C.G. de Bruin, Paul M.P. van Bergen en Henegouwen,

Immunology

2016

21

Enhancement of NK Cell Antitumor Effector Functions Using a Bispecific Single Domain Antibody Targeting CD16 and the Epidermal Growth Factor Receptor

Elisa C. Toffoli, Abdolkarim Sheikhi, Roeland Lameris,

Cancers

2021

21

Page 1